The Administrative Core will be responsible for the overall management of this IPCAVD program according to PAR-06-286. The Administrative Core will be responsible for interacting with the DAIDS Program Officer and Staff as required by the U19 funding mechanism as a multi-project cooperative agreement between our team and NIH. The Administrative Core will also perform its duty to coordinate all aspects of routine program management on administrative, financial, regulatory, and clinical issues. The Administrative Core will organize and interact with external advisors, and host annual external reviews.
Aim 1 : To coordinate the interactions a) among scientists from different institutions included in the current program, and b) between our team and NIH personnel regarding efficient implementation of proposed plans and projects.
Aim 2 : To oversee all budgetary matters, including review and approval of subcontract agreements negotiated through the Project Management Group (PMG) of Project 3, and the monitoring of monthly expenses and preparation of various reports.
Aim 3 : To maintain records of pre-IND and IND application documents with the US FDA and coordinate efforts in IND filing and clinical protocol reviews required by different agencies, institutions, and committees.
Aim 4 : To work with HVTN to improve, implement, and execute the Clinical Development Plan including the timely start of clinical testing at HVTN of our modified multi-gene, polyvalent HIV vaccine formulation to be developed by this application.
Aim 5 : Information management: to provide bioinformatics and statistical support, to develop an Intellectual Property plan, and plans to promote data standardization, data and resource sharing.
|Marty-Roix, Robyn; Vladimer, Gregory I; Pouliot, Kimberly et al. (2016) Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem 291:1123-36|
|Costa, Matthew R; Pollara, Justin; Edwards, Regina Whitney et al. (2016) Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. J Virol 90:10362-10378|
|Suschak, John J; Wang, Shixia; Fitzgerald, Katherine A et al. (2016) A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol 196:310-6|
|Pan, Ruimin; Chen, Yuxin; Vaine, Michael et al. (2015) Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. Emerg Microbes Infect 4:e44|
|Suschak, John J; Wang, Shixia; Fitzgerald, Katherine A et al. (2015) Identification of Aim2 as a sensor for DNA vaccines. J Immunol 194:630-6|
|Zhang, Lu; Wang, Wei; Wang, Shixia (2015) Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 14:1509-23|
|Hollister, Kristin; Chen, Yuxin; Wang, Shixia et al. (2014) The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother 10:1985-92|
|Pouliot, Kimberly; Buglione-Corbett, Rachel; Marty-Roix, Robyn et al. (2014) Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine 32:5049-56|
|Buglione-Corbett, Rachel; Pouliot, Kimberly; Marty-Roix, Robyn et al. (2014) Reduced MyD88 dependency of ISCOMATRIXâ„¢ adjuvant in a DNA prime-protein boost HIV vaccine. Hum Vaccin Immunother 10:1078-90|
|Chen, Yuxin; Vaine, Michael; Wallace, Aaron et al. (2013) A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol 87:10232-43|
Showing the most recent 10 out of 22 publications